microbiome drug News
-
MetaboGen at the Microbiome Drug Development Summit, Paris Jan 24-25
On January 24-26, MetaboGen will attend the 1st Microbiome Drug Development Summit Europe, taking place in Paris. Meet us there! Read more: ...
By Metabogen AB
-
Microviable will be attending Pharmabiotics Event 2022
Our CEO Claudio Hidalgo will be attending the Pharmabiotics Event 2022 taking place on April 20th-21st at Lyon. The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to meet stakeholders and discuss the further innovation in microbiome-based drug products and regulatory affairs. Reach out to us if you want to meet during the ...
-
Bio-Me represented with two presentations at the 6th Microbiome Movement – Drug Development Summit 2021
On July 1st Bio-Me has two back-to-back presentations. Our Founder and CEO, Morten L. Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. Following that, our COO Warren Flood will do a joint presentation with Ricardo Valladares, CSO at Siolta Therapeutics showcasing ...
By Bio-Me
-
EnteroBiotix Expands Headcount and Premises to Advance Microbiome Drug Pipeline
EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial therapeutics, and an expansion of its corporate offices to support an ...
-
Symberix Co-Founder Gives Keynote Address at AACR Conference
Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keynote, titled “Molecular control of the gut ...
-
Symberix Awarded Multiple Grants from National Institutes of Health to Expand Platform of Microbiome-Targeted Drugs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational ...
-
MV BioTherapeutics to present at the 6th Microbiome Movement - Drug Development Europe
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022. The presentation has been included in stream A titled “Understanding mechanisms of action & preclinical development” the 26th at 13.45. Microbiota Adaptation ...
-
Symberix Awarded $2 Million from National Institutes of Health to Support Lead Program
Symberix has been awarded the Phase II portion of a Small Business Innovation Research (SBIR) Fast-Track grant from the National Institutes of Health (NIH). The NIH Fast-Track application process expedites award decisions and funding of Phase II applications that have a high potential for commercialization by allowing Phase I and Phase II grant applications to be submitted and reviewed together. ...
-
EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product ...
-
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic ...
-
Dr. Ryan Gordon joins the Stem Pharm team as Sr. V.P. of Business Development
Dr. Ryan Gordon has joined the Stem Pharm team as Sr. V.P. of Business Development and Commercialization. Gordon brings to Stem Pharm over 20 years of business, R&D, and operational experience in developing and commercializing innovative biopharmaceutical technologies to revolutionize disease treatment and improve patient outcomes. He has been a valued leader at large companies (3M) and ...
-
Symberix Awarded Multiple SBIR Grants from National Institutes of Health to Develop Proprietary Microbiome-Targeted Drugs
Symberix, a leader in the discovery of drugs that selectively target the human microbiome, announced today that it has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). These grants will fund the research of new drugs that safely and selectively inhibit a bacterial enzyme responsible for a number of dose-limiting gastrointestinal (GI) ...
-
MV BioTherapeutics to present at 5th Microbiome Movement - Drug Development Europe
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021. The presentation has been included in the morning stream titled “Introducing the Era of Engineered Microbes” the 29th at 11.35. Leveraging Gut Microbiota ...
-
Symberix Announces Non-Dilutive Funding Support for Lead Programs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), entered into a Research Collaboration Agreement with the NIH’s National Center for Advancing Translational Sciences (NCATS), and ...
-
Bio-Me Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the ...
By Bio-Me
-
LISCure`s Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...
-
SFA Therapeutics, Inc. announces start of phase 1B clinical trial in the treatment of mild-to-moderate plaque psoriasis
SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to psoriasis.” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial. This 30-subject open-label clinical trial in patients with ...
-
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of ...
-
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) ...
-
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you